Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Reason for suspension of trades in IMCB shares was their growth

2/16/24 GEMA

OGK-2 reported for 2023 by RAS

2/16/24 OGKB

Seligdar selects technology for processing Kyuchus ores

2/16/24 SELG

Pharmsintez sold the Estonian plant to the chairman of the board of directors

2/16/24 LIFE

Maria Shevchenko resigns as Chief Operating Officer of Qiwi

2/16/24 QIWI

NKNH postponed launch of hexene production to mid-2025

2/16/24 NKNC

NKNH's increased its share of domestic sales to 71%

2/16/24 NKNC

MMK increased supplies to the domestic market by 18%

2/16/24 MAGN

Moscow Exchange to lose control in NTPro

2/16/24 MOEX

Saratovenergo has multiplied profit

2/16/24 SARE